$MRK, Eisai Get FDA's Complete Response Letter for Combo KEYTRUDA + LENVIMA as First-Line Treatment for Unresectable Hepatocellular Carcinoma    #Merck   #MSD   #Eisai    #Carcinoma       https://t.co/8b7i4NVvvC